American Society of Hirudotherapy

The molecular basis of thrombin allostery revealed by a 1.8 A structure of the "slow" form

Research article published in Structure (London, England : 1993) (2003)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentSalivary PharmacologyHuntington et al. · Structure (London, England : 1993), 2003

Abstract

Thrombin participates in its own positive and negative feedback loops, and its allosteric state helps determine the hemostatic balance. Here we present the 1.8 A crystallographic structure of S195A thrombin in two conformational states: active site occupied and active site free. The active site-occupied form shows how thrombin can accommodate substrates, such as protein C. The active site-free form is in a previously unobserved closed conformation of thrombin, which satisfies all the conditions of the so-called "slow" form. A mechanism of allostery is revealed, which relies on the concerted movement of the disulphide bond between Cys168 and 182 and aromatic residues Phe227, Trp215, and Trp60d. These residues constitute an allosteric switch, which is flipped directly through sodium binding, resulting in the fast form with an open active site.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAllosteric RegulationBinding SitesCrystallography, X-RayHumansModels, MolecularProtein ConformationSodiumThrombinTime Factors

Summary

A 1.8 A structure of S195A thrombin in active-site-occupied and free states reveals a closed, previously unobserved 'slow' conformation and a sodium-triggered allosteric switch (Cys168-Cys182, Phe227, Trp215, Trp60d) that opens the active site.

Context

This study presented a 1.8 Å crystal structure of the S195A thrombin mutant in two conformational states—active site occupied and active site free—revealing a previously unobserved closed conformation satisfying conditions of the 'slow' form. The authors identified an allosteric switch involving the Cys168-Cys182 disulfide bond and aromatic residues Phe227, Trp215, and Trp60d that is flipped directly through sodium binding, resulting in the fast form with an open active site. The work advances understanding of thrombin allosteric regulation relevant to coagulation biology broadly. No hirudin, leech-derived compounds, or hirudotherapy are mentioned anywhere in the abstract.

Citation

Reference (Vancouver style)

Huntington JA, Esmon CT. The molecular basis of thrombin allostery revealed by a 1.8 A structure of the "slow" form. Structure. 2003;11(4):469-479. doi:10.1016/s0969-2126(03)00049-2. PMID: 12679024

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.